Cuba launches clinic for chikungunya aftereffects

The Institute of Neurology and Neurosurgery in Cuba has begun a specialized clinic to care for patients with post-chikungunya ailments, particularly those linked to neuropathic pain, joint pain, and paresthesia. This step provides focused treatment for individuals impacted by the mosquito-borne virus.

In Havana on December 23, the Institute of Neurology and Neurosurgery in Cuba has launched a specialized clinic dedicated to treating patients with post-chikungunya ailments. The facility focuses on conditions such as neuropathic pain, joint pain, and paresthesia, which are common lingering effects of the mosquito-borne chikungunya virus that causes fever and severe aches.

Chikungunya can lead to long-term complications that impair daily life for those infected. The new clinic aims to address these persistent issues through comprehensive care. As reported by Prensa Latina, this opening meets the demand for specialized health services in Cuba.

While specific patient numbers are not yet available, the clinic is part of Cuba's public health efforts to manage infectious diseases and their neurological aftermaths. This initiative highlights Cuba's dedication to accessible medical treatment for virus-related conditions.

Articoli correlati

Comparative illustration of long COVID patients: US woman with severe brain fog and anxiety versus milder symptoms in India, Nigeria, and Colombia, per international study.
Immagine generata dall'IA

International study finds U.S. long COVID patients report more brain fog and psychological symptoms than peers in India and Nigeria

Riportato dall'IA Immagine generata dall'IA Verificato

A Northwestern Medicine-led study of more than 3,100 adults with long COVID found that non-hospitalized participants in the United States reported substantially higher rates of brain fog, depression/anxiety and insomnia than participants in Colombia, Nigeria and India—differences the researchers say likely reflect cultural factors and access to care as much as biology.

Il presidente cubano Miguel Díaz-Canel ha presentato risultati preliminari positivi dalle prove cliniche del farmaco biotecnologico Jusvinza in pazienti con artrite cronica post-chikungunya. Gli studi, avviati a dicembre 2025, mostrano miglioramenti notevoli in province come L'Avana e Matanzas. Gli esperti evidenziano il profilo di sicurezza del farmaco e il suo potenziale per rallentare l'infiammazione.

Riportato dall'IA

Cuba ha una situazione epidemiologica favorevole nella lotta contro gli arbovirus, dopo una diminuzione del 21% dei casi febbrili segnalati la settimana scorsa. Questo miglioramento evidenzia gli sforzi efficaci per controllare le malattie trasmesse da vettori come la dengue e la zika. Le autorità sanitarie sottolineano la necessità di una vigilanza continua.

Kenya's Ministry of Health has warned citizens against non-essential travel to parts of India following confirmation of two Nipah virus cases in West Bengal. The risk of the disease spreading to Kenya remains low, but authorities urge strict personal hygiene for travelers. The World Health Organization has verified the outbreak of this rare but serious illness.

Riportato dall'IA

In Brazil's shrinking Atlantic Forest, deforestation is causing mosquitoes to increasingly feed on humans, heightening the risk of diseases like dengue and Zika. A new study reveals that out of identified blood meals, most came from people rather than wildlife. This adaptation underscores how habitat loss alters disease transmission patterns.

Researchers from Weill Cornell Medicine and Wake Forest University School of Medicine have identified a stress-response pathway in immune cells that is activated by chemotherapy and leads to painful nerve damage. In mice, blocking this pathway with a drug already in early-stage cancer trials reduced signs of nerve injury, and a small patient study suggests a blood test might one day predict who is most at risk.

Riportato dall'IA

L'Area Sanitaria Don Benito ha confermato il decesso di un adolescente di 15 anni per meningoencefalite causata dalla riattivazione del virus di tipo 6. Il decesso è avvenuto il 13 marzo presso l'ospedale Vegas Altas. Le autorità sanitarie affermano che questa variante non richiede sorveglianza epidemiologica o protocolli specifici.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta